CollPlant Biotechnologies (CLGN) Q4 2024 earnings summary

Executive summary

• Advanced proprietary programs in regenerative medicine and aesthetics, including a photocurable dermal filler and regenerative breast implants, with positive preclinical results and strong market potential; breast implant program targets a $3B market and showed promising six-month preclinical data.

• Collaboration with AbbVie on dermal and soft tissue filler continues, with AbbVie conducting clinical trials and a recent $2 million milestone payment received in February 2025.

• Expanded distribution network for Vergenix STR in Europe and Asia, targeting the sports medicine market for tendon injuries, with new distribution agreements signed.

• Implemented cost-cutting and workforce reduction plan, reducing workforce by 20%.

• Secured new patents in Japan and the US for rhCollagen biolinks and photocurable dermal filler.

Financial highlights

• 2024 GAAP revenues were $515,000, down from $11 million in 2023, mainly due to a $10 million AbbVie milestone payment in 2023.

• 2024 GAAP net loss was $16.6 million ($1.45 per share), compared to $7 million ($0.62 per share) in 2023; non-GAAP net loss was $14.9 million ($1.30 per share) vs. $5.2 million ($0.46 per share).

• Q4 2024 GAAP revenues were $164,000, down from $299,000 in Q4 2023, mainly due to lower rhCollagen sales.

• Cash and cash equivalents at year-end 2024 were $11.9 million, with an additional $2 million received from AbbVie in Q1 2025.

• Cash used in operating activities in 2024 was $14.1 million, up from $2.8 million in 2023.

Outlook and guidance

• Cash runway expected to support operations through at least Q2 2026, not including potential new partnership revenues.

• Plans to launch a clinical trial for the photocurable dermal filler within two years.

• Continued optimization of regenerative breast implants and expansion of Vergenix STR distribution in Europe and Asia.

• Focus on expanding BioInk offerings and rhCollagen sales to select customers.